184 related articles for article (PubMed ID: 23546415)
1. What future does the pharmaceutical industry have in the cardiovascular world?
Braunwald E
Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
[No Abstract] [Full Text] [Related]
2. Merck Serono targets convenient, affordable medicines for patients at risk.
Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
[No Abstract] [Full Text] [Related]
3. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
Gagnon JP
Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
[No Abstract] [Full Text] [Related]
4. Corporate influence over planning and presentation of clinical trials: beauty and the beast.
Fuchs FD
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):7-9. PubMed ID: 20014930
[No Abstract] [Full Text] [Related]
5. Cardiovascular combinations.
Glass G
Nat Rev Drug Discov; 2004 Sep; 3(9):731-2. PubMed ID: 15368657
[No Abstract] [Full Text] [Related]
6. Cardiovascular pipeline decline quantified.
Mullard A
Nat Rev Drug Discov; 2016 Sep; 15(10):669. PubMed ID: 27681785
[No Abstract] [Full Text] [Related]
7. Promises kept and broken: new pharmaceuticals.
Malik P
Can J Cardiol; 2002 May; 18(5):493-4. PubMed ID: 12032574
[No Abstract] [Full Text] [Related]
8. Has the European union achieved a single pharmaceutical market?
Timur A; Picone G; DeSimone J
Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacoeconomics and cardiovascular disease].
Anguita Sánchez M
Rev Clin Esp; 2004 Aug; 204(8):391-2. PubMed ID: 15274760
[No Abstract] [Full Text] [Related]
10. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
11. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones.
Shantsila A; Lip GY
Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004
[No Abstract] [Full Text] [Related]
12. Future opportunities & innovative therapies for cardiovascular disease-SMi conference.
Mazucco RA
IDrugs; 2004 Jan; 7(1):31-3. PubMed ID: 14968813
[No Abstract] [Full Text] [Related]
13. Past the wall in cardiovascular R&D.
Topol EJ
Nat Rev Drug Discov; 2009 Apr; 8(4):259. PubMed ID: 19348004
[No Abstract] [Full Text] [Related]
14. ACE inhibitors: back to prime time?
Gupta M; Verma S; Mancini GB
Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166
[No Abstract] [Full Text] [Related]
15. PHARMAC and cardiovascular health in New Zealand.
Moodie P
N Z Med J; 2008 Mar; 121(1270):102-5. PubMed ID: 18364762
[No Abstract] [Full Text] [Related]
16. Discontinued drugs in 2008: cardiovascular drugs.
Zhang XS; Xiang BR
Expert Opin Investig Drugs; 2009 Jul; 18(7):875-85. PubMed ID: 19548849
[TBL] [Abstract][Full Text] [Related]
17. The pharmaceutical industry in the Arab world: challenges, controversies, and future outlook.
Kandil O
Drug Discov Today; 2004 Jul; 9(13):543-5. PubMed ID: 15203084
[No Abstract] [Full Text] [Related]
18. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
Detsky AS
Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
[No Abstract] [Full Text] [Related]
19. Market watch: sales trends by therapeutic area: 2008-2013E.
Goodman M
Nat Rev Drug Discov; 2009 Sep; 8(9):689. PubMed ID: 19721440
[No Abstract] [Full Text] [Related]
20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
Temple R
Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
